OPKO Health (OPK) Receives Consensus Recommendation of “Hold” from Analysts

Shares of OPKO Health (NASDAQ:OPK) have received an average rating of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $12.10.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. BidaskClub upgraded OPKO Health from a “strong sell” rating to a “sell” rating in a report on Friday, January 26th. JPMorgan Chase lowered OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price on the stock. in a report on Friday, March 2nd. ValuEngine lowered OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, Cantor Fitzgerald set a $20.00 target price on OPKO Health and gave the stock a “buy” rating in a report on Thursday, March 1st.

Shares of OPK stock traded down $0.09 on Friday, hitting $3.08. 2,608,579 shares of the stock were exchanged, compared to its average volume of 3,841,671. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.14 and a quick ratio of 0.98. The stock has a market capitalization of $1,723.18, a P/E ratio of -10.62 and a beta of 1.56. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.90.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The firm had revenue of $193.70 million for the quarter, compared to analyst estimates of $307.44 million. OPKO Health had a negative return on equity of 7.87% and a negative net margin of 28.93%. equities analysts expect that OPKO Health will post -0.48 EPS for the current year.

In other OPKO Health news, Director Robert Scott Fishel acquired 15,000 shares of the company’s stock in a transaction on Monday, April 16th. The shares were purchased at an average price of $3.01 per share, for a total transaction of $45,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Phillip Md Et Al Frost acquired 10,000 shares of the company’s stock in a transaction on Thursday, April 19th. The stock was acquired at an average price of $3.17 per share, for a total transaction of $31,700.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $9,728,574.67. The disclosure for this purchase can be found here. Insiders have purchased 1,996,365 shares of company stock worth $7,097,858 in the last quarter. 40.19% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its stake in OPKO Health by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,657 shares during the period. Ellington Management Group LLC bought a new stake in OPKO Health in the fourth quarter valued at approximately $112,000. State of Alaska Department of Revenue bought a new stake in OPKO Health in the fourth quarter valued at approximately $144,000. First Trust Advisors LP bought a new stake in OPKO Health in the fourth quarter valued at approximately $154,000. Finally, Xact Kapitalforvaltning AB bought a new stake in OPKO Health in the fourth quarter valued at approximately $179,000. Hedge funds and other institutional investors own 23.38% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3379847/opko-health-opk-receives-consensus-recommendation-of-hold-from-analysts.html.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Analyst Recommendations for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TopBuild  Hits New 52-Week High and Low at $84.52
TopBuild Hits New 52-Week High and Low at $84.52
Nu Skin Enterprises  Sets New 52-Week High and Low at $81.72
Nu Skin Enterprises Sets New 52-Week High and Low at $81.72
Jaguar Health  Shares Gap Down to $0.14
Jaguar Health Shares Gap Down to $0.14
ValuEngine Downgrades LG Display  to Strong Sell
ValuEngine Downgrades LG Display to Strong Sell
GTX  Upgraded at ValuEngine
GTX Upgraded at ValuEngine
Community Health Systems  Upgraded at ValuEngine
Community Health Systems Upgraded at ValuEngine


© 2006-2018 Ticker Report. Google+.